maintained in serum-free medium were treated with 25 mIU/ml heparitinase 1 hr before BMP addition and throughout the remainder of the assay. Cells were then stimulated with human recombinant BMP4 at 5 ng/ml for 1 hr. Cells lysates were subjected to immunoblotting for P-Smad. Data are from triplicate cultures ± S.D (error bars) for each condition, and are normalized to total Smad. Smad phosphorylation in response to BMP4 was substantially lower in heparitinase-treated cells than in untreated cells (*; P < 0.01; ttest). (B) Exogenous heparin does not rescue cells from the effect of heparitinase treatment. C2C12 cells were treated with heparitinase for 1 hr, and BMP4 (5 ng/ml), or BMP4 and heparin (3-100 µg/ml) were added for a subsequent hour. Cell lysates were subjected to immunoblotting for P-Smad, and band intensities were quantified. Data are from duplicate cultures for each condition and are normalized to total Smad in cells.
Supplemental Figure 2. Kinetic profiles of BMP2-induced p38 activation. C2C12 (A)
or PC12 cells (B) were treated with heparitinase for 1 hr, and BMP2 (5 ng/ml) was added.
Cell lysates were collected at indicated time points and subjected to immunoblotting for activated p38. Data are normalized to total p38 in cells. Membrane BMP2 heparinbinding domain ("unstructured") 
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